• Home

• Small Molecules: Hit identification

• Small Molecules: Hit-to-Lead optimization

• Small Molecules: physicochemical properties

• Small Molecules: ADME

• Small Molecules: Toxicity

• Small Molecules: Selectivity

• Antibodies: Humanization and Optimization

• Protein Modeling. Discovery

• Protein Modeling: HERG binding

• Protein Modeling: Albumin binding

• Quantum Discussions Forum    

You access the old version of our website. Please point your browser to our new home page.

Quantum Pharmaceuticals is pleased to offer biotech and pharmaceutical companies a unique product developed in collaboration with InterBioScreen – a collection of Q-Lead-Targeted Libraries™. Each Q-Lead-Library™ is a library of compounds, which are ranked according to their constant affinity to a particular protein disease target.

Molecules at the top of the list have the highest affinity, are hits for the protein and may be advanced to further drug optimization. We have dozens of Q-Lead-Libraries™ for many diseases including Cancer, Alzheimer, AIDS and Diabetes. Each Q-Lead-Targeted Library™ consists of thousands of natural and synthetic compounds with different levels of bioactivity (pmol, nmol, mkmol) for the target protein.

The Q-Lead project™ is enhanced by collaborations with major Russian research centers such as the Institute of Cytology RAS , N.Bach Institute of Biochemistry RAS , A.N. Belozersky Institute of Physico-Chemical Biology , and the Kurchatov Research Center as well as the expertise of more than 1500 researchers operating in 7 offices and 9 basic research laboratories.

Other Q-Lead™ products and services may be found at the QuantumLead™ web site.